• Forest Laboratories Inc., of New York, and Almirall SA, of Barcelona, Spain, said the FDA will require a three-month extension to complete its review of the new drug application for aclidinium bromide, a long-acting antimuscarinic drug, for the maintenance treatment of chronic obstructive pulmonary disease.